Special Issue

Mitochondria in Human Health and Diseases

Message from the Guest Editor

Mitochondria, an energy center integrating with other organelles, contribute to a variety of cellular activities and stress responses through their dynamic properties such as fusion, fission and mitophagy, leading to the maintenance of cellular homeostasis. Recent advances in mitochondrial biology demonstrate that mitochondria not only act as organelles of "a cellular power plant" for ATP production to energize cellular/molecular activities of daily life, but also circulate in human peripheral blood and function as novel mediators involved in the crosstalk among different cells, tissues, and organs in physiological and pathological conditions. This Special Issue focuses on recent progress in basic research and clinical studies of mitochondria to facilitate their translational potential in clinics. Researchers and clinicians are encouraged to submit insightful reviews and research papers on the topic of mitochondria.

Guest Editor

Dr. Yong Zhao Throne Biotechnologies, Paramus, NJ 07652, USA

Deadline for manuscript submissions

closed (31 July 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/182486

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).